AtaiBeckley
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. It was formed in November 20251 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited, and has been a wholly owned subsidiary of Eli Lilly and Company since September 2026.
See also
List of psychedelic pharmaceutical companies List of investigational hallucinogens and entactogens
Text derived from https://en.wikipedia.org/w/index.php?oldid=1375700300 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “AtaiBeckley” date of formation (×1) · confidence 0.95 revision URL